Abstract
ObjectiveTo explore the antibiotic resistance of Brucella melitensis and instruct rational use of antimicrobial agents in clinical treatment of Brucella infection. MethodsBacteria were cultured and identified by BACTEC9120 and VITEK II automicrobic system. E–test was used to detect the minimal inhibitory concentration (MIC) of antimicrobial agents in the drug susceptivity experiment. ResultsA total of 19 brucella strains (all Brucella melitensis) were isolated from 19 patients, who had fever between January 2010 and June 2012, and 17 samples were blood, one was bone marrow, the other sample was cerebrospinal fluid. The MIC range of ceftazidime was 2.0–8.0 mg/L, rifampicin was 0.06–2.0 mg/L, amikacin was 4.0–12.0 mg/L, levofloxacin was 2.0–8.0 mg/L, doxycycline was 8.0–32.0 mg/L, sulfamethoxazole–trimethoprim was 4.0–16.0 mg/L, ampicillin was 1.5–2.0 mg/L and gentamicin was 0.50–0.75 mg/L. ConclusionsThe drugs used in this experiment cover common drugs for treating Brcella. Meanwhile, the results are consistent with clinical efficacy. It is suggested personalized regimen according to patients' status in treatment of Brucella.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
